Regorafenib combined with irinotecan as second -line treatment in patients with metastatic gastro-oesophageal adenocarcinomas: A randomized phase 2 trial (PRODIGE 58-UCGI 35-REGIRI)

Affiliation auteurs!!!! Error affiliation !!!!
TitreRegorafenib combined with irinotecan as second -line treatment in patients with metastatic gastro-oesophageal adenocarcinomas: A randomized phase 2 trial (PRODIGE 58-UCGI 35-REGIRI)
Type de publicationJournal Article
Year of Publication2019
AuteursSamalin E., Turpin A., Khemissa F., Zaanan A., Benabdelghani M., Senellart H., Gilabert M., Evesque L., Dahan L., Sefrioui D., Bouche O., de la Fouchardiere C., Hennequin A., Monard L., Gourgou S., Lopez A.
JournalANNALS OF ONCOLOGY
Volume30
Date PublishedJUL
Type of ArticleMeeting Abstract
ISSN0923-7534
DOI10.1093/annonc/mdz155.079